Evidence map›Paper›PMID 35008529›Full record

ArticleInternational journal of molecular sciences2021

miR-205-5p Downregulation and

Lenka Kalinkova, Nataliia Nikolaieva, Bozena Smolkova, Sona Ciernikova, Karol Kajo, Vladimir Bella, Viera Horvathova Kajabova, Helena Kosnacova, Gabriel Minarik, Ivana Fridrichova

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. The consensus molecular subtypes of esophageal squamous cell carcinoma.Signal transduction and targeted therapy · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. miRNA in Molecular Diagnostics.Bioengineering (Basel, Switzerland) · 2022
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Lenka KalinkovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Nataliia NikolaievaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Bozena SmolkovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.ORCID 0000-0002-4906-5652
Sona CiernikovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.ORCID 0000-0002-8139-6945
Karol KajoDepartment of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.ORCID 0000-0002-8178-1093
Vladimir BellaDepartment of Senology, St. Elisabeth Cancer Institute, 81250 Bratislava, Slovakia.
Viera Horvathova KajabovaDepartment of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.ORCID 0000-0002-7081-0602
Helena KosnacovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.ORCID 0000-0001-8384-3510
Gabriel MinarikInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81108 Bratislava, Slovakia.
Ivana FridrichovaDepartment of Genetics, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences, 84505 Bratislava, Slovakia.ORCID 0000-0001-7581-1770
Cancer Research Institute of the Slovak Academy of Sciences · SKComenius University Bratislava · SKVysoká Škola Zdravotníctva a Sociálnej Práce sv. Alžbety · SK

Funding

Scientific Grant Agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic and the Slovak Academy of Sciences VEGA 2/0036/19
6 · The paper itself

Abstract

backgroundDissemination of breast cancer (BC) cells through the hematogenous or lymphogenous vessels leads to metastatic disease in one-third of BC patients. Therefore, we investigated the new prognostic features for invasion and metastasis.

methodsWe evaluated the expression of miRNAs and epithelial-to-mesenchymal transition (EMT) genes in relation to

resultsWe did not verify

conclusionsmiR-205-5p and potentially

Indexed as

3' Untranslated RegionsAdultAgedAged, 80 and overBreast NeoplasmsCarcinoma, Ductal, BreastCell Line, TumorCell MovementCell ProliferationDown-RegulationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMicroRNAs3' Untranslated RegionsMicroRNAsMIR205, humanZEB1 protein, humanZinc Finger E-box-Binding Homeobox 1CDH1 geneE-cadherinEMT genesinvasive ductal breast cancermiRNA and mRNA expression

Identifiers

PMID35008529
PMCPMC8744876
OpenAlexW4200328824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.